Innovent

Innovent Biologics (Suzhou) Co., Ltd. was established in August 2011. It is committed to becoming the best biopharmaceutical company in China and a world-class leader in high-end biologics, developing and producing affordable high-end biologics for the general public. The company has secured up to $490 million in investments from globally renowned venture capital firms, creating a new model of leveraging global capital to support innovation.After five years of development, Innovent Bio has focused on innovation and built a product pipeline comprising 13 novel drug candidates, covering four major disease areas: oncology, ocular diseases, autoimmune diseases, and cardiovascular diseases. The company has undertaken seven national scientific projects, with five products selected for China's "Major New Drug Development" initiative and one product included in the "Precision Medicine Research" key R&D program. It has constructed a large-scale industrial base, including two 1,000L production lines (already completed), six 3,000L lines (under construction), and four 15,000L lines (under construction), all compliant with GMP standards set by CFDA, FDA, and EMA. The two 1,000L production lines passed the GMP audit by an international pharmaceutical group partner in September 2016, marking the first biologics production line in China to meet U.S. FDA GMP standards. Additionally, the company has assembled a team of highly skilled professionals in biologics development and commercialization, featuring over 50 experts who have returned from overseas.